| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
9.73(B) |
| Last
Volume: |
909,295 |
Avg
Vol: |
504,661 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,500 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$238,260 |
$238,260 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
25,597 |
29,385 |
30,235 |
146,471 |
| Total Sell Value |
$5,039,534 |
$5,596,862 |
$5,742,535 |
$29,817,809 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
4 |
5 |
6 |
17 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kuriyel Ralf |
Senior VP, R&D |
• – – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
404 |
27,480 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
391 |
29,178 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
19,719 |
214,026 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,520 |
27,076 |
|
- |
|
| Loeillot Olivier |
President and CCO |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,880 |
15,786 |
|
- |
|
| Garland Jason K |
CFO |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,540 |
8,043 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,691 |
22,826 |
|
- |
|
| Dawes Karen A |
|
– • – |
2024-02-27 |
4 |
S |
$193.35 |
$193,350 |
D/D |
(1,000) |
87,367 |
|
15% |
|
| Dawes Karen A |
|
– • – |
2024-02-27 |
4 |
OE |
$42.07 |
$194,616 |
D/D |
4,626 |
88,367 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-02-23 |
4 |
S |
$198.08 |
$866,204 |
D/D |
(4,373) |
14,135 |
|
16% |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-02-23 |
4 |
OE |
$94.33 |
$88,670 |
D/D |
940 |
18,508 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• – – |
2023-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
194,307 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2023-11-10 |
4 |
S |
$147.13 |
$557,328 |
D/D |
(3,788) |
28,787 |
|
-34% |
|
| Loeillot Olivier |
President and CCO |
• – – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,906 |
12,906 |
|
- |
|
| Garland Jason K |
CFO |
• – – |
2023-09-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,503 |
5,503 |
|
- |
|
| Dawes Karen A |
|
– • – |
2023-08-29 |
4 |
S |
$171.38 |
$145,673 |
D/D |
(850) |
83,741 |
|
-3% |
|
| Dawes Karen A |
|
– • – |
2023-08-29 |
4 |
OE |
$18.12 |
$133,943 |
D/D |
7,392 |
84,591 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
798 |
77,199 |
|
- |
|
| Muir Glenn P |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
686 |
7,582 |
|
- |
|
| Konstantinov Konstantin |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
686 |
1,220 |
|
- |
|
| Eglinton Manner Carrie |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
686 |
2,167 |
|
- |
|
| Barthelemy Nicholas |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
686 |
2,767 |
|
- |
|
| Mhatre Rohin |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
686 |
2,345 |
|
- |
|
| Madaus Martin D |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
686 |
2,297 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2023-05-16 |
4 |
D |
$154.03 |
$109,361 |
D/D |
(710) |
37,381 |
|
- |
|
464 Records found
|
|
Page 2 of 19 |
|
|
5.84 (3.56%) 
